Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series.
Document Type
Article
Abstract
Management of chemotherapy-induced thrombocytopenia (CIT) is challenging, often resulting in chemotherapy treatment delays, dose reduction, and treatment interruption. Randomized trials support the potential efficacy and safety of thrombopoietin receptor agonists in CIT management. A phase III trial of avatrombopag (AVA) demonstrated increased platelet counts (PC) in patients with solid tumours experiencing CIT. To complement those findings, this case series of six patients with solid tumours and CIT is presented. Results from these cases support the clinical benefit of AVA in improving PC and reducing the impact of CIT on tumour treatment, allowing continued therapy without dose reduction or treatment interruption.
Publication Date
10-21-2024
Publication Title
British journal of haematology
ISSN
1365-2141
PubMed ID
39434457
Digital Object Identifier (DOI)
10.1111/bjh.19797
Recommended Citation
Galamaga, Robert; Johnston, Stephanie; and Acosta, Cassaundra, "Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series." (2024). Neurology. 1899.
https://scholar.barrowneuro.org/neurology/1899